Skip to main content

Table 1 Clinicopathological features of the patients included in the differential expression analyses

From: miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil

CharacteristicsHBCSBCNBT
BRCA1BRCA2BRCAXn = 23BRCA1/2WT
n = 15n = 14n = 14n = 5n = 3
Clinical
 Age at diagnosis, y
  Mean (SD)43.73 (8.30)44.57 (11.18)41.78 (12.14)48.73 (10.45)41.80 (5.89)58.00 (9.16)
  Range29–5926–6725–6630–7735–5150–68
Pathological, n (%)
 Grade (SBR)*
..  .11 (6,7)01 (7.1)0  
..  .24 (26.7)5 (35.7)6 (42.9)3 (13)  
...  310 (66.7)9 (64.3)7 (50)20 (87)  
ER*
 Negative12 (80)4 (28.6)5 (35.7)17 (73.9)  
 Positive3 (20)10 (71.4)9 (64.3)6 (26.1)  
PR*
 Negative11 (73.3)6 (42.9)7 (50)19 (82,6)  
 Positive4 (26.7)8 (57.1)7 (50)4 (17.4)  
HER2 amplification*
 Negative14 (93.3)12 (85.7)11 (78.6)19 (82,6)  
 Positive1 (6.7)2 (14.3)3 (21.4)4 (17.4)  
Molecular subtype*
 Luminal4 (26.7)11 (78.6)9 (64.3)6 (26.1)  
 HER2+002 (14.3)1 (4.3)  
 Triple-negative11 (73.3)3 (21.4)4 (21.4)16 (69.6)  
TNM*
 I2 (13.3)03 (21.4)1 (4.3)  
 II9 (60)4 (28.6)9 (64.3)11 (47.8)  
 III3 (20)8 (57.1)1 (7.1)10 (43.5)  
 IV1 (6.7)2 (14.3)1 (7.1)1 (4.3)  
  1. (*) For breast tumors only.
  2. HBC, hereditary breast cancer; SBC, sporadic breast cancer; NBT, normal breast tissue; WT, wild-type; y, years; SD, standard deviation; SBR, Scarff-Bloom-Richardson; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.